Repligen (NASDAQ:RGEN) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a report published on Friday morning.

Several other research analysts have also recently issued reports on the company. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $185.20.

Repligen Stock Up 4.8 %

Shares of Repligen stock opened at $149.90 on Friday. Repligen has a one year low of $113.50 and a one year high of $211.13. The company has a market cap of $8.40 billion, a P/E ratio of -405.12, a PEG ratio of 4.64 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a fifty day moving average of $144.96 and a two-hundred day moving average of $142.20.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the company posted $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts forecast that Repligen will post 1.54 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

A number of large investors have recently bought and sold shares of the stock. Everence Capital Management Inc. acquired a new stake in shares of Repligen during the fourth quarter valued at $294,000. GAMMA Investing LLC boosted its stake in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Repligen by 8.7% during the third quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company’s stock worth $47,551,000 after buying an additional 26,668 shares in the last quarter. Peapack Gladstone Financial Corp acquired a new position in shares of Repligen in the third quarter valued at approximately $296,000. Finally, Tidal Investments LLC lifted its stake in shares of Repligen by 142.8% during the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 6,558 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.